Welcome to LookChem.com Sign In|Join Free

CAS

  • or

97974-23-7

Post Buying Request

97974-23-7 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

97974-23-7 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 97974-23-7 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 9,7,9,7 and 4 respectively; the second part has 2 digits, 2 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 97974-23:
(7*9)+(6*7)+(5*9)+(4*7)+(3*4)+(2*2)+(1*3)=197
197 % 10 = 7
So 97974-23-7 is a valid CAS Registry Number.

97974-23-7SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 20, 2017

Revision Date: Aug 20, 2017

1.Identification

1.1 GHS Product identifier

Product name (2S)-2-[tert-butyl(diphenyl)silyl]oxypropan-1-ol

1.2 Other means of identification

Product number -
Other names 1-Propanol,2-[[(1,1-dimethylethyl)diphenylsilyl]oxy]-,(S)

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:97974-23-7 SDS

97974-23-7Relevant articles and documents

A concise total synthesis of amphidinolide T2

Li, Huoming,Wu, Jinlong,Luo, Jialu,Dai, Wei-Min

supporting information; experimental part, p. 11530 - 11534 (2010/11/24)

RCM+AD=T2: In the presence of the C16-methylene group, regioselective ring-closing metathesis (RCM) formed the (12E)-endocyclic double bond, which underwent Os-catalyzed asymmetric dihydroxylation (AD) to give the desired 12,13-diol intermediate required

Altered transition state for the reaction of an RNA model catalyzed by adinuclear zinc(II) catalyst

Morrow, Janet R.,Richard, John P.,et al.,Humphry, Tim,Iyer, Subashree,Iranzo, Olga

experimental part, p. 17858 - 17866 (2009/08/08)

The cyclization of 2-(hydroxypropyl)-4-nitrophenyl phosphate (HpPNP) catalyzed by the dinuclear zinc complex of 1,3-bis(1,4,7-triazacyclonon-1-yl)-2- hydroxypropane (1) proceeds by a transition state that is different from that of the uncatalyzed reaction. Kinetic isotope effects (KIEs) measured in the nucleophilic atom and in the leaving group show that theuncatalyzed cyclization has a transition state (TS) with little phospho rus-oxygen bond fission to the leaving group 18klg= 1.0064 ± 0.0009 and 15k = 1.0002 ± 0.0002) a nd that nucleophilic bond formation occurs in the rate-determining step (18knuc ) 1.0326 ( 0.0008). In the catalyzed reaction, larger leaving group isotope effects ( 18klg ) 1.0113 ± 0.0005 and 15k = 1.0015 ± 0.0005) and a smaller nucleophile isotope effect (18k nuc = 1.0116 ± 0.0010) indicate a later TS with greater leaving group bond fission and greater nucleophilic bond formation. These observed nucleophile KIEs are the combined effect of the equilibrium effect on deprotonation of the 2′-hydroxyl nucleophile and the KIE on the nucleophilic step. An EIE of 1.0245 for deprotonation of the hydroxyl group of HPpNP was obtained computationally. The different KIEs for the two reactions indicate that the effective catalysis by 1 is accompanied by selection for an altered transition state, presumably arising from the preferential stabilization by the catalyst of charge away from the nucleophile and toward the leaving group. These results demonstrate the potential fora catalyst using biologically relevant metal ions to select for an alte red transition state for phosphoryl transfer.

MACROCYCLIC COMPOUNDS USEFUL AS PHARMACEUTICALS

-

Page/Page column 134-135, (2010/02/07)

The present invention provides compounds having formula (I), and additionally provides methods for the synthesis thereof and methods for the use thereof in the treatment of various disorders including inflammatory or autoimmune disorders, and disorders involving malignancy or increased angiogenesis, wherein R1 -R11, t, X, Y, Z, and n are as defined herein.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 97974-23-7